-
Barclays Expects M&A In Specialty Pharma To Continue, Likes Valeant And Jazz
Thursday, July 9, 2015 - 8:56am | 555Read More...In a report published Wednesday, Barclays analyst Douglas Tsao detailed why he believes that M&A activity within the Specialty Pharmaceutical sector is expected to continue. According to Tsao, much of the consolidation seen in the industry has been driven by "strategic considerations" rather...
-
Firms Bullish On Valeant Following Earnings, Acquisition
Tuesday, February 24, 2015 - 2:44pm | 320Read More...Monday saw many biotech firms surging, among them was Valeant Pharmaceuticals Intl Inc (NYSE: VRX) after acquiring Salix Pharmaceuticals Ltd. (NYSE: SLXP). In Tuesday morning summaries, many firms lauded Valeant's earnings report. Of the different reasons for the increased price...
-
Zoetis Flexes Muscles; Has "Pipeline Power," Says Barclays
Thursday, February 12, 2015 - 12:29pm | 144Read More...Barclays on Thursday gave a Healthcare spotlight on Zoetis Inc (NYSE: ZTS) after the biotech company reported fourth quarter earnings of $0.40 per share, beating analyst estimates of $0.37 EPS. Zoetis also reported fourth quarter revenues of $1.32 billion, again beating consensus estimates of $1....
-
NuVasive (NUVA) Maintains Its Rating From Barclays
Tuesday, February 2, 2010 - 2:32pm | 125Read More...Analysts Douglas D. Tsao at Barclays Capital (ADR) (NYSE: BCS) released an update on NuVasive Inc. (NASDAQ: NUVA) yesterday. NuVasive Inc. pre-released, on Friday, the results for the fourth quarter and maintained its guidance for FY10. The company indicated that the fourth quarter EPS would be $0...
